CAPN12 Gene Expression as a Molecular Discriminator
CAPN12 Gene Expression as a Molecular Discriminator Between Methotrexate Treated Chronic Plaque Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.
Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.
Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.
CAPN12 is a calcium-dependent cysteine protease expressed in the epidermis and hair follicles and implicated in skin barrier biology and keratinocyte differentiation. Recent integrative single-cell RNA sequencing and Mendelian randomization work identified CAPN12 among genetically informed psoriasis related candidate genes and linked it to increased psoriasis susceptibility.
The same work reported that these candidate genes were predominantly expressed in CD4+ T cells, supporting the feasibility of peripheral blood mononuclear cell-based expression assessment .
Because methotrexate can modulate immune-cell activity, this study will restrict patient recruitment to methotrexate-treated patients on a stable regimen. This design aims to explore whether CAPN12 expression can discriminate between methotrexate-treated cutaneous-only psoriasis and methotrexate-treated psoriatic arthritis, and whether CAPN12 expression correlates with clinical activity indices.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Sherine Adly Hashem, MSc
- 電話番号:+201011000258
- メール:Sherry.adly.7@gmail.com
研究連絡先のバックアップ
- 名前:Soheir Abdel Hamid Ali, M.D
- 電話番号:+201066877345
- メール:Soher.abdelhamed@med.svu.edu.eg
研究場所
-
-
-
Qina、エジプト
- 募集
- South Valley University Hospital
-
コンタクト:
- Mohamed Hosney Hassan, Professor
- 電話番号:+201006393764
- メール:mohammedhosneyhassan@med.svu.edu.eg
-
コンタクト:
- Amr Mohamed Alnoby Aldowy, Lecturer
- 電話番号:+201017789975
- メール:Amrnoby1990@gmail.com
-
副調査官:
- Shimaa Saber Ahmed, M.D
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
- Type of the study: Case-control molecular study.
- Study Setting: Qena University Hospital, Department of Dermatology, Venereology& Andrology and Rheumatology Clinics.
- Study subjects: This study will include adult participants recruited from the outpatient Dermatology and Rheumatology Clinics.
- Receiver operating characteristic curve analysis will be used to evaluate the diagnostic performance of CAPN12 expression.
- Multivariate logistic regression may be performed to test whether CAPN12 expression is independently associated with psoriatic arthritis status.
説明
Inclusion Criteria:
- Patients aged 18 -70 years.
- The severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity).
- Confirmed diagnosis: Psoriasis vulgaris (PsV) or Psoriatic arthritis (PsA) diagnosed by a dermatologist/rheumatologist.
- Willingness to participate: Signed informed consent.
- Patients on stable dose of methotrexate (MTX) therapy.
- Availability for follow-up: Patients must be willing and able to attend scheduled visit.
Exclusion Criteria:
- Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Pregnancy and lactation.
- Patients currently undergoing immunosuppressive or systemic therapies.
- Patients with known genetic disorders affect immune system function.
- Patients with liver or kidney impairment.
- Patients with allergy or contraindication to methotrexate.
- Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
- Previous genetic analysis: Patients who have previously undergone genetic analysis for the CAPN12 gene expression.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_CONTROL
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Chronic plaque psoriasis group
About 35 patients suffering from chronic plaque psoriasis and clinically diagnosed chronic plaque psoriasis receiving a stable methotrexate regimen for at least 12 weeks, with no clinical evidence of psoriatic arthritis.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
他の名前:
|
|
Psoriatic arthritis group
About 35 patients suffering from Psoriatic arthritis and diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) and receiving a stable methotrexate regimen for at least 12 weeks.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
他の名前:
|
|
Healthy Control group
About 35 participants inwhich age- and sex-matched apparently healthy individuals with no history of psoriasis, psoriatic arthritis, other autoimmune or chronic inflammatory diseases, and no history of methotrexate therapy. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
CAPN12 mRNA expression
時間枠:3 Months
|
Assessment of the Difference in relative CAPN12 mRNA expression among the three studied groups. |
3 Months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain Relief
時間枠:3 Months
|
Assessment of the patients of the study from the pain after treatment using Visual Analogue Scale (VAS) where as 0 for none up to 10 for very severe |
3 Months
|
協力者と研究者
捜査官
捜査官
- スタディチェア:Eisa Mohammed Hegazy, M.D、Professor of Dermatology,Venereology and Andrology,Faculty of Medicine
- スタディディレクター:Marwa Alyan Abdelaziz Mohammed, M.D、Lecturer of Dermatology,Venereology and Andrology,Faculty of Medicine
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CAPN12 Gene Expression
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。